Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia

Results of a phase II GIMEMA study (AML-1107)

Sergio Amadori, Roberto Stasi, Alberto M. Martelli, Adriano Venditti, Giovanna Meloni, Fabrizio Pane, Giovanni Martinelli, Monia Lunghi, Livio Pagano, Daniela Cilloni, Elena Rossetti, Francesco Di Raimondo, Claudio Fozza, Luciana Annino, Francesca Chiarini, Francesca Ricci, Emanuele Ammatuna, Edoardo La Sala, Paola Fazi, Marco Vignetti

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The mammalian target of rapamycin (mTOR) signalling pathway has emerged as an important therapeutic target for acute myeloid leukaemia (AML). This study assessed the combination of temsirolimus, an mTOR inhibitor, and lower-dose clofarabine as salvage therapy in older patients with AML. Induction consisted of clofarabine 20mg/m 2 on days 1-5 and temsirolimus 25mg (flat dose) on days 1, 8 and 15. Patients achieving complete remission with (CR) or without (CRi) full haematological recovery could receive monthly temsirolimus maintenance. In 53 evaluable patients, the overall remission rate (ORR) was 21% (8% CR, 13% CRi). Median disease-free survival was 3·5months, and median overall survival was 4months (9·1months for responders). The most common non-haematological severe adverse events included infection (48%), febrile neutropenia (34%) and transaminitis (11%). The 30-d all-cause induction mortality was 13%. Laboratory data from 25 patients demonstrated that a >50%in vivo inhibition of S6 ribosomal protein phosphorylation was highly correlated with response rate (75% with inhibition versus 0% without inhibition; P=0·0001), suggesting that targeting the mTOR pathway is clinically relevant. The acceptable safety profile and the predictive value of target inhibition encourage further investigation of this novel regimen.

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalBritish Journal of Haematology
Volume156
Issue number2
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Salvage Therapy
Sirolimus
Acute Myeloid Leukemia
Ribosomal Protein S6
Febrile Neutropenia
Disease-Free Survival
Maintenance
Phosphorylation
Safety
Survival
Mortality
clofarabine
temsirolimus
Infection
Therapeutics

Keywords

  • Acute myeloid leukaemia
  • Clofarabine
  • Elderly patients
  • Mammalian target of rapamycin
  • Temsirolimus

ASJC Scopus subject areas

  • Hematology

Cite this

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia : Results of a phase II GIMEMA study (AML-1107). / Amadori, Sergio; Stasi, Roberto; Martelli, Alberto M.; Venditti, Adriano; Meloni, Giovanna; Pane, Fabrizio; Martinelli, Giovanni; Lunghi, Monia; Pagano, Livio; Cilloni, Daniela; Rossetti, Elena; Di Raimondo, Francesco; Fozza, Claudio; Annino, Luciana; Chiarini, Francesca; Ricci, Francesca; Ammatuna, Emanuele; La Sala, Edoardo; Fazi, Paola; Vignetti, Marco.

In: British Journal of Haematology, Vol. 156, No. 2, 01.2012, p. 205-212.

Research output: Contribution to journalArticle

Amadori, S, Stasi, R, Martelli, AM, Venditti, A, Meloni, G, Pane, F, Martinelli, G, Lunghi, M, Pagano, L, Cilloni, D, Rossetti, E, Di Raimondo, F, Fozza, C, Annino, L, Chiarini, F, Ricci, F, Ammatuna, E, La Sala, E, Fazi, P & Vignetti, M 2012, 'Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a phase II GIMEMA study (AML-1107)', British Journal of Haematology, vol. 156, no. 2, pp. 205-212. https://doi.org/10.1111/j.1365-2141.2011.08940.x
Amadori, Sergio ; Stasi, Roberto ; Martelli, Alberto M. ; Venditti, Adriano ; Meloni, Giovanna ; Pane, Fabrizio ; Martinelli, Giovanni ; Lunghi, Monia ; Pagano, Livio ; Cilloni, Daniela ; Rossetti, Elena ; Di Raimondo, Francesco ; Fozza, Claudio ; Annino, Luciana ; Chiarini, Francesca ; Ricci, Francesca ; Ammatuna, Emanuele ; La Sala, Edoardo ; Fazi, Paola ; Vignetti, Marco. / Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia : Results of a phase II GIMEMA study (AML-1107). In: British Journal of Haematology. 2012 ; Vol. 156, No. 2. pp. 205-212.
@article{e44649791dde42a78e2a1328ea378fb2,
title = "Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a phase II GIMEMA study (AML-1107)",
abstract = "The mammalian target of rapamycin (mTOR) signalling pathway has emerged as an important therapeutic target for acute myeloid leukaemia (AML). This study assessed the combination of temsirolimus, an mTOR inhibitor, and lower-dose clofarabine as salvage therapy in older patients with AML. Induction consisted of clofarabine 20mg/m 2 on days 1-5 and temsirolimus 25mg (flat dose) on days 1, 8 and 15. Patients achieving complete remission with (CR) or without (CRi) full haematological recovery could receive monthly temsirolimus maintenance. In 53 evaluable patients, the overall remission rate (ORR) was 21{\%} (8{\%} CR, 13{\%} CRi). Median disease-free survival was 3·5months, and median overall survival was 4months (9·1months for responders). The most common non-haematological severe adverse events included infection (48{\%}), febrile neutropenia (34{\%}) and transaminitis (11{\%}). The 30-d all-cause induction mortality was 13{\%}. Laboratory data from 25 patients demonstrated that a >50{\%}in vivo inhibition of S6 ribosomal protein phosphorylation was highly correlated with response rate (75{\%} with inhibition versus 0{\%} without inhibition; P=0·0001), suggesting that targeting the mTOR pathway is clinically relevant. The acceptable safety profile and the predictive value of target inhibition encourage further investigation of this novel regimen.",
keywords = "Acute myeloid leukaemia, Clofarabine, Elderly patients, Mammalian target of rapamycin, Temsirolimus",
author = "Sergio Amadori and Roberto Stasi and Martelli, {Alberto M.} and Adriano Venditti and Giovanna Meloni and Fabrizio Pane and Giovanni Martinelli and Monia Lunghi and Livio Pagano and Daniela Cilloni and Elena Rossetti and {Di Raimondo}, Francesco and Claudio Fozza and Luciana Annino and Francesca Chiarini and Francesca Ricci and Emanuele Ammatuna and {La Sala}, Edoardo and Paola Fazi and Marco Vignetti",
year = "2012",
month = "1",
doi = "10.1111/j.1365-2141.2011.08940.x",
language = "English",
volume = "156",
pages = "205--212",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia

T2 - Results of a phase II GIMEMA study (AML-1107)

AU - Amadori, Sergio

AU - Stasi, Roberto

AU - Martelli, Alberto M.

AU - Venditti, Adriano

AU - Meloni, Giovanna

AU - Pane, Fabrizio

AU - Martinelli, Giovanni

AU - Lunghi, Monia

AU - Pagano, Livio

AU - Cilloni, Daniela

AU - Rossetti, Elena

AU - Di Raimondo, Francesco

AU - Fozza, Claudio

AU - Annino, Luciana

AU - Chiarini, Francesca

AU - Ricci, Francesca

AU - Ammatuna, Emanuele

AU - La Sala, Edoardo

AU - Fazi, Paola

AU - Vignetti, Marco

PY - 2012/1

Y1 - 2012/1

N2 - The mammalian target of rapamycin (mTOR) signalling pathway has emerged as an important therapeutic target for acute myeloid leukaemia (AML). This study assessed the combination of temsirolimus, an mTOR inhibitor, and lower-dose clofarabine as salvage therapy in older patients with AML. Induction consisted of clofarabine 20mg/m 2 on days 1-5 and temsirolimus 25mg (flat dose) on days 1, 8 and 15. Patients achieving complete remission with (CR) or without (CRi) full haematological recovery could receive monthly temsirolimus maintenance. In 53 evaluable patients, the overall remission rate (ORR) was 21% (8% CR, 13% CRi). Median disease-free survival was 3·5months, and median overall survival was 4months (9·1months for responders). The most common non-haematological severe adverse events included infection (48%), febrile neutropenia (34%) and transaminitis (11%). The 30-d all-cause induction mortality was 13%. Laboratory data from 25 patients demonstrated that a >50%in vivo inhibition of S6 ribosomal protein phosphorylation was highly correlated with response rate (75% with inhibition versus 0% without inhibition; P=0·0001), suggesting that targeting the mTOR pathway is clinically relevant. The acceptable safety profile and the predictive value of target inhibition encourage further investigation of this novel regimen.

AB - The mammalian target of rapamycin (mTOR) signalling pathway has emerged as an important therapeutic target for acute myeloid leukaemia (AML). This study assessed the combination of temsirolimus, an mTOR inhibitor, and lower-dose clofarabine as salvage therapy in older patients with AML. Induction consisted of clofarabine 20mg/m 2 on days 1-5 and temsirolimus 25mg (flat dose) on days 1, 8 and 15. Patients achieving complete remission with (CR) or without (CRi) full haematological recovery could receive monthly temsirolimus maintenance. In 53 evaluable patients, the overall remission rate (ORR) was 21% (8% CR, 13% CRi). Median disease-free survival was 3·5months, and median overall survival was 4months (9·1months for responders). The most common non-haematological severe adverse events included infection (48%), febrile neutropenia (34%) and transaminitis (11%). The 30-d all-cause induction mortality was 13%. Laboratory data from 25 patients demonstrated that a >50%in vivo inhibition of S6 ribosomal protein phosphorylation was highly correlated with response rate (75% with inhibition versus 0% without inhibition; P=0·0001), suggesting that targeting the mTOR pathway is clinically relevant. The acceptable safety profile and the predictive value of target inhibition encourage further investigation of this novel regimen.

KW - Acute myeloid leukaemia

KW - Clofarabine

KW - Elderly patients

KW - Mammalian target of rapamycin

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84155180788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155180788&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08940.x

DO - 10.1111/j.1365-2141.2011.08940.x

M3 - Article

VL - 156

SP - 205

EP - 212

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -